Prostate Cancer

The FDA has granted approval to oral relugolix as treatment of patients with advanced prostate cancer.

During a Targeted Oncology Case Based Peer Perspectives event, Daniel J. George, MD, professor of Medicine, professor in Surgery Member, Duke Cancer Institute Department of Medicine Duke University School of Medicine, discuss various hormonal therapies for the treatment of prostate cancer.

The phase 1/2 study of the investigational chimeric antigen receptor T-cell agent BPX-601 administered as treatment of patients with previously treated metastatic pancreatic or prostate cancer is no longer active after the FDA place a partial clinical hold on the trial.

Ulka Vaishampayan, MD, discusses the excitement surrounding PSMA radioligand therapy in the prostate cancer space.

A significantly longer overall survival was observed with olaparib in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM, compared with those who received enzalutamide or abiraterone plus prednisone, according to research presented at the 21st Annual Meeting of the Society of Urologic Oncology.

Treatment with enzalutamide in combination with androgen deprivation therapy led to a clinically meaningful decrease in the risk of death for patients with non-metastatic castration resistance prostate cancer.

In a presentation during the 21st Annual Meeting of the Society of Urologic Oncology, Kara N. Maxwell, MD, PhD, expanded upon the available biomarkers for use in prostate cancer and how they can be applied at various points and for guiding toward which treatments can improve care of patients with prostate cancer.

Enzalutamide achieved both an improvement in progression-free survival and an increase in time to PSA progression compared with bicalutamide as treatment of patients with nonmetastatic castration-resistant prostate cancer.

Declan Murphy, MD, discusses the current interest in using PSMA, following the FDA’s approval of Gallium 68 PSMA-11, which marks the first ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer.

The FDA approved Gallium 68 PSMA-11 as the first ever drug for PET imaging of PSMA positive lesions in men with prostate cancer.

Naomi Haas, MD, discusses the importance of using PSMA, an antigen that is expressed on the cell surface, for the detection of prostate cancer.

Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.

The FDA granted a Fast Track designation to RV001 for the potential treatment of patients with prostate cancer.

During a Targeted Oncology Case Based Peer Perspectives event, Alicia K. Morgans, MD, MPH, reviewed 2 cases of patients with nonmetastatic castration resistant prostate cancer and explained the potential testing and treatment options.

In an interview with Targeted Oncology, Sarki Abdulkadir, MD, PhD, discussed the emerging role of the MYC protein as a target for the treatment of patients with prostate cancer.

Monica L. Baskin, PhD, addresses the biggest challenges in treating patients with prostate cancer during the COVID-19 era.

The FDA expanded approval of FoundationOne® Liquid CDx as a companion diagnostic for olaparib, which is currently indicated for use as treatment in patients with BRCA1/2 and/or ATM alterations in metastatic castration-resistant prostate cancer.

In the treatment landscape of metastatic castration resistant prostate cancer, the introduction of PARP inhibitors as a therapeutic option has led to progress, explained Maha Hussain, MD, in a presentation during the 38th Annual Chemotherapy Foundation Symposium.